Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis

Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by clonal proliferation of differentiated myeloid cells leading to bone marrow fibrosis, cytopenias and extramedullary hematopoiesis. In late 2019, the FDA approved the highly selective JAK2 inhibitor, fedratinib, for intermediate-2 o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bewersdorf, Jan Philipp, Jaszczur, Sara Mohamed, Afifi, Salma, Zhao, Jennifer C, Zeidan, Amer M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935287/
https://www.ncbi.nlm.nih.gov/pubmed/31920387
http://dx.doi.org/10.2147/CMAR.S212559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935287/
https://www.ncbi.nlm.nih.gov/pubmed/31920387
http://dx.doi.org/10.2147/CMAR.S212559

Ejemplares similares